Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

The first multiple stent delivery system for the treatment of biliary, pancreatic and urologic strictures and stenosis

Objetivo

Gastrointestinal diseases affect more than 70 M of people only in US and many of them, e.g. biliary/pancreatic disorders, can have as a consequence biliary, pancreatic or other duct's narrowing (stenosis). In these cases, there is an urgent need to restore lumen patency and drainage in order to prevent complications (e.g. jaundice, infections, liver disease), and they are often treated long-term by stent placement with an ERCP (Endoscopic Retrograde Cholangio-Pancreatography). However, ERCP stenting (specially for multiple stents) still represents many potential complications, associated with extended procedural times and multiple cannulations, which increases the side-effects of the procedure and the ERCP and post-ERCP costs. EndoGI medical has developed the first patented multi-stent delivery system for treatment of biliary, pancreatic and urologic stenosis that allows the safe insertion of multiple plastic stents (MPS) in a controlled, secure and single step. It enables the insertion of 2 or more plastic stents in the bile, hepatic or urinary ducts at 1 endoscope passage and with securing the guidewire throughout the procedure. EndoGI system can reduce up to 50% the cost of hospitalization/day, up to 80% the cost of hospitalization derived from post-ERCP pancreatitis and up to 20% the costs of hospitalizations by ischemia, which represents a 64% of reduction in comparison with common procedure using MPS and 2 delivery systems. We have built-up a first prototype and preliminary tested it with human phantoms and pig models, and now we aim to optimize the device, completely validate it in clinical settings, obtain regulatory certifications and launch it to market. We will initially penetrate the non-vascular stents market and focus in biliary stenting to offer savings of ˞€330 M/year only in EU. During Phase 1, we will carry out a detailed feasibility study to evaluate the opportunities our innovation has to disrupt the field and boost EndoGI company growth.

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-1

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

ENDO GI MEDICAL LTD
Aportación neta de la UEn
€ 50 000,00
Dirección
13 WADI EL HAJ
16000 NAZARETH
Israel

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00